Skip to main content
. 2019 Oct 3;14(10):e0223530. doi: 10.1371/journal.pone.0223530

Fig 4. Ranking plot based simultaneously on efficacy (x-axis: SUCRA value of overall survival) and tolerability (y-axis: 1-SUCRA value of serious adverse events).

Fig 4

SUCRA, surface under the cumulative ranking curves; TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.